Patients with AIG: demographics and clinicopathological profile
| Variable | T1 211 patients | Female 160 (75.8%) | Male 51 (24.2%) | T2 211 patients | Female 160 (75.8%) | Male 51 (24.2%) |
| Age: Mean (SD); median | 55.7 (1 4.1); 56 | 54.5 (14.3); 55 | 59.7 (13.0); 63 | 63.3 (13.3); 64 | 62.2 (13.5); 62 | 66.5 (12.5); 67 |
| H. pylori status (serology, histology, molecular biology on tissue samples) | All negative | 160 | 51 | All negative | 160 | 51 |
| Follow-up (years): mean (SD); median | 7.5 (4.4); 7 | 7.7 (4.5); 7 | 7.0 (4.1); 6 | |||
| OLGA staging | ||||||
| 0 | 8 (3.8%) | 8 | 0 | 7 (3.3%) | 6 | 1 |
| I | 23 (10.9%) | 19 | 4 | 19 (9.0%) | 16 | 3 |
| II | 179 (84.8%) | 132 | 47 | 175 (82.9%) | 129 | 46 |
| III | 1 (0.5%) | 1 | 0 | 10 (4.7%) | 9 | 1 |
| IV | 0 | 0 | 0 | 0 | 0 | 0 |
| IEN | ||||||
| Absent | 210 | 209 | ||||
| Low grade | 1 (FAP) | 2 (1 FAP) | ||||
| High grade | 0 | 0 | ||||
| ECL status | ||||||
| Within normal limits | 20 | 15 | 5 | 24 | 19 | 5 |
| Diffuse hyperplasia linear/micronodular | 167 | 130 | 37 | 151 | 109 | 42 |
| Adenomatoid hyperplasia/dysplasia | 14 | 11 | 3 | 25 | 22 | 3 |
| Type1-NET | 10 | 4 | 6 | 11 | 10 | 1 |
ECL, enterochromaffin like cells; FAP, familial adenomatous polyposis; IEN, intraepithelial neoplasia; T1, time of the index biopsy set; T2, time of the last check-up; Type1-NET, type 1 neuroendocrine tumours.